1
|
Ramirez-Tagle R, Salgado-Moran G, Mendez-Luna D, Correa-Basurto J, Villada WC, Candia LG, Mendoza-Huizar LH. SYNTHESIS, CHEMICAL IDENTIFICATION, DRUG RELEASE AND DOCKING STUDIES OF THE AMLODIPINE–CHITOSAN NANOBIOPOLYMER COMPOSITE. J Chil Chem Soc 2021. [DOI: 10.4067/s0717-97072021000105063] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
2
|
Martínez-Pacheco H, Ramírez-Galicia G, Vergara-Arias M, Gertsch J, Fragoso-Vazquez JM, Mendez-Luna D, Abujamra AL, Cristina CPL, Cecilia RHM, Mendoza-Lujambio I, Correa-Basurto J. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8. Anticancer Agents Med Chem 2017; 17:927-940. [PMID: 27774878 DOI: 10.2174/1871520616666161019143219] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Revised: 09/30/2016] [Accepted: 10/04/2016] [Indexed: 11/22/2022]
Abstract
BACKGROUND Histone deacetylase 8 (HDAC8) is a plausible target for the development of novel anticancer drugs using a metal-chelating group and hydrophobic moieties as pharmacophores. It is known that valproic acid (administered as its salt, sodium valproate; VPANa+) is an HDAC8 inhibitor characterized by its hydrophobic chains. Nevertheless, VPA is hepatotoxic and VPA analogues might be explored for less hepatotoxic antiproliferative compounds. METHOD In this work, docking and QSAR studies of 500 aryl-VPA derivatives as possible HDAC8 inhibitors were performed in order to explore and select potential anti-proliferative compounds. Docking results identified π-π, hydrogen bonds as the most important noncovalent interactions between HDAC8 (PDB: 3F07) and the ligands tested, whereas Belm4 was the best QSAR descriptor and classified as a 2D-BCUT descriptor. RESULT Based on theoretical studies, compound DAVP042 was synthesized and evaluated in vitro for its antiproliferative activities on several cancer cell lines (A549-lung, MCF-7-breast, HCT116-colon and U937- lymphoid tissue) in comparison to VPA, as well as for its inhibitory activity on HDAC8 using in vitro models. DAVP042 demonstrated to have antiproliferative activity on all cancer cell lines employed, not only suggesting that this compound should be further studied, but also demonstrating that the methodology herein employed is appropriated to identify new therapeutic candidates.
Collapse
Affiliation(s)
- Heidy Martínez-Pacheco
- Universidad del Papaloapan, Circuito Central 200, Parque Industrial, 68301 Tuxtepec, Oaxaca. Mexico
| | - Guillermo Ramírez-Galicia
- Instituto de Química Aplicada, Universidad del Papaloapan, Circuito Central 200, Parque Industrial, 68301 Tuxtepec, Oaxaca. Mexico
| | - Midalia Vergara-Arias
- Laboratorio de Modelado Molecular y Diseño de Fármacos (Laboratory of Molecular Modelling and Drug Design), Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón s/n, Casco de Santo Tomás, Mexico City, 11340. Mexico
| | - Jurg Gertsch
- Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, CH-3012 Bern. Switzerland
| | - Jonathan Manuel Fragoso-Vazquez
- Departamento de Química Orgánica, Escuela Nacional de Ciencias, Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala, Col. Casco de Santo Thomas. Mexico
| | - David Mendez-Luna
- Laboratorio de Modelado Molecular y Diseño de Fármacos (Laboratory of Molecular Modelling and Drug Design), Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón s/n, Casco de Santo Tomás, Mexico City, 11340. Mexico
| | - A L Abujamra
- Graduate Program in Biotechnology, UNIVATES, Rio Grande do Sul. Brazil
| | - Cabrera-Perez Laura Cristina
- Laboratorio de Modelado Molecular y Diseño de Fármacos (Laboratory of Molecular Modelling and Drug Design), Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón s/n, Casco de Santo Tomás, Mexico City, 11340. Mexico
| | - Rosales-Hernandez Martha Cecilia
- Laboratorio de Modelado Molecular y Diseño de Fármacos (Laboratory of Molecular Modelling and Drug Design), Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón s/n, Casco de Santo Tomás, Mexico City, 11340. Mexico
| | - I Mendoza-Lujambio
- Laboratorio de Modelado Molecular y Diseño de Fármacos (Laboratory of Molecular Modelling and Drug Design), Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón s/n, Casco de Santo Tomás, Mexico City, 11340. Mexico
| | - Jose Correa-Basurto
- Laboratorio de Modelado Molecular y Diseño de Fármacos (Laboratory of Molecular Modelling and Drug Design), Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón s/n, Casco de Santo Tomás, Mexico City, 11340. Mexico
| |
Collapse
|
3
|
Calzada F, Solares-Pascasio JI, Ordoñez-Razo RM, Velazquez C, Barbosa E, García-Hernández N, Mendez-Luna D, Correa-Basurto J. Antihyperglycemic Activity of the Leaves from Annona cherimola Miller and Rutin on Alloxan-induced Diabetic Rats. Pharmacognosy Res 2017; 9:1-6. [PMID: 28250646 PMCID: PMC5330092 DOI: 10.4103/0974-8490.199781] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Background: Annona cherimola, known as “chirimoya” has been reported in Mexican traditional medicine for the treatment of diabetes. Objective: The aims of the present study were to validate and assess the traditional use of A. cherimola as an antidiabetic agent. Materials and Methods: The ethanol extract from A. cherimola (300 mg/kg, EEAc), subsequent fractions (100 mg/kg), and rutin (30 mg/kg) were studied on alloxan-induced type 2 diabetic (AITD) and normoglycemic rats. In addition, oral glucose tolerance test (OGTT) and oral sucrose tolerance test (OSTT) were performed in normoglycemic rats. Molecular docking technique was used to conduct the computational study. Results: Bioassay-guided fractionation of EEAc afforded as major antihyperglycemic compound, rutin. EEAc attenuated postprandial hyperglycemia in acute test using AITD rats (331.5 mg/dL) carrying the glycemic levels to 149.2 mg/dL. Rutin after 2 h, attenuated postprandial hyperglycemia in an acute assay using AITD rats such as EEAc, with maximum effect (150.0 mg/dL) being seen at 4 h. The antihyperglycemic activities of EEAc and rutin were comparable with acarbose (151.3 mg/dL). In the subchronic assay on AITD rats, the EEAc and rutin showed a reduction of the blood glucose levels since the 1st week of treatment, reaching levels similar to normoglycemic state (116.9 mg/kg) that stayed constant for the rest of the assay. OGTT and OSTT showed that EEAc and rutin significantly lowered blood glucose levels in normoglycemic rats at 2 h after a glucose or sucrose load such as acarbose. Computational molecular docking showed that rutin interacted with four amino acids residues in the enzyme α-glucosidase. Conclusion: The results suggest that rutin an α-glucosidase inhibitor was responsible in part of the antihyperglycemic activity of A. cherimola. Its in vivo antihyperglycemic activity is in good agreement with the traditional use of A. cherimola for the treatment of diabetes. SUMMARY The ethanol extract from Annona cherimola (300 mg/kg, EEAc), subsequent fractions (100 mg/kg) and rutin (30 mg/kg) were studied on alloxan-induced type 2 diabetic (AITD) and normoglycemic rats. The results suggest that rutin; an α-glucosidase inhibitor was responsible in part of the antihyperglycemic activity of A. cherimola. Its in vivo antihyperglycemic activity is in good agreement with the traditional use of A. cherimola for the treatment of diabetes.
Abbreviations Used: EEAc: The ethanol extract from Annona cherimola, AITD: Alloxan-induced type 2 diabetic rats, OGTT: Oral glucose tolerance test, OSTT: Oral sucrose tolerance test, DM: Diabetes mellitus
Collapse
Affiliation(s)
- Fernando Calzada
- Medical Research Unit in Pharmacology, UMAE Speciality Hospital-2° Floor CORCE National Medical Center Siglo XXI, IMSS, Av. Cuauhtemoc 330, Col. Doctores, CP 06725, México City, México
| | - Jesús Iván Solares-Pascasio
- Medical Research Unit in Pharmacology, UMAE Speciality Hospital-2° Floor CORCE National Medical Center Siglo XXI, IMSS, Av. Cuauhtemoc 330, Col. Doctores, CP 06725, México City, México
| | - R M Ordoñez-Razo
- Medical Research Unit in Human Genetics UMAE Pediatric Hospital. Medical Center Siglo XXI, IMSS, México City, México
| | - Claudia Velazquez
- Institute of Health Sciences, Autonomous University of the State of Hidalgo, Km. 4.5 Carretera Pachuca-Tulancingo, Unidad Universitaria, C. P. 42076 Pachuca, Hidalgo, México
| | - Elizabeth Barbosa
- Postgraduate Studies and Research, Superior School of Medicine of IPN, Plan de San Luís y Díaz Mirón, CP 11340, México City, México
| | - Normand García-Hernández
- Medical Research Unit in Human Genetics UMAE Pediatric Hospital. Medical Center Siglo XXI, IMSS, México City, México
| | - David Mendez-Luna
- Laboratory of Molecular Modeling and Bioinformátics/ Drug Design, Superior School of Medicine of IPN, Plan de San Luis y Díaz Mirón s/n, 11340 México City, México
| | - José Correa-Basurto
- Laboratory of Molecular Modeling and Bioinformátics/ Drug Design, Superior School of Medicine of IPN, Plan de San Luis y Díaz Mirón s/n, 11340 México City, México
| |
Collapse
|
4
|
Moreno-Ulloa A, Mendez-Luna D, Beltran-Partida E, Castillo C, Guevara G, Ramirez-Sanchez I, Correa-Basurto J, Ceballos G, Villarreal F. The effects of (-)-epicatechin on endothelial cells involve the G protein-coupled estrogen receptor (GPER). Pharmacol Res 2015; 100:309-20. [PMID: 26303816 DOI: 10.1016/j.phrs.2015.08.014] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 08/17/2015] [Accepted: 08/18/2015] [Indexed: 02/05/2023]
Abstract
We have provided evidence that the stimulatory effects of (-)-epicatechin ((-)-EPI) on endothelial cell nitric oxide (NO) production may involve the participation of a cell-surface receptor. Thus far, such entity(ies) has not been fully elucidated. The G protein-coupled estrogen receptor (GPER) is a cell-surface receptor that has been linked to protective effects on the cardiovascular system and activation of intracellular signaling pathways (including NO production) similar to those reported with (-)-EPI. In bovine coronary artery endothelial cells (BCAEC) by the use of confocal imaging, we evidence the presence of GPER at the cell-surface and on F-actin filaments. Using in silico studies we document the favorable binding mode between (-)-EPI and GPER. Such binding is comparable to that of the GPER agonist, G1. By the use of selective blockers, we demonstrate that the activation of ERK 1/2 and CaMKII by (-)-EPI is dependent on the GPER/c-SRC/EGFR axis mimicking those effects noted with G1. We also evidence by the use of siRNA the role that GPER has on mediating ERK1/2 activation by (-)-EPI. GPER appears to be coupled to a non Gαi/o or Gαs, protein subtype. To extrapolate our findings to an ex vivo model, we employed phenylephrine pre-contracted aortic rings evidencing that (-)-EPI can mediate vasodilation through GPER activation. In conclusion, we provide evidence that suggests the GPER as a potential mediator of (-)-EPI effects and highlights the important role that GPER may have on cardiovascular system protection.
Collapse
Affiliation(s)
- Aldo Moreno-Ulloa
- University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA, USA; Laboratorio de Investigación Integral Cardiometabólica, Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico
| | - David Mendez-Luna
- Laboratorio de modelado Molecular y Diseño de Fármacos, Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico
| | | | - Carmen Castillo
- Laboratorio de Investigación Integral Cardiometabólica, Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico
| | - Gustavo Guevara
- Laboratorio de Investigación Integral Cardiometabólica, Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico
| | - Israel Ramirez-Sanchez
- University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA, USA; Laboratorio de Investigación Integral Cardiometabólica, Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico
| | - José Correa-Basurto
- Laboratorio de modelado Molecular y Diseño de Fármacos, Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico; Laboratorio de Investigación Integral Cardiometabólica, Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico
| | - Guillermo Ceballos
- Laboratorio de Investigación Integral Cardiometabólica, Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico
| | - Francisco Villarreal
- University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA, USA.
| |
Collapse
|
5
|
Luna-Palencia G, Martinez-Ramos F, Vasquez-Moctezuma I, Fragoso-Vazquez M, Mendieta-Wejebe J, Padilla-Martínez I, Sixto-Lopez Y, Mendez-Luna D, Trujillo-Ferrara J, Meraz-Rios M, Fonseca-Sabater Y, Correa-Basurto J. Three Amino Acid Derivatives of Valproic Acid: Design, Synthesis, Theoretical and Experimental Evaluation as Anticancer Agents. Anticancer Agents Med Chem 2014; 14:984-93. [DOI: 10.2174/1871520614666140127113218] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2013] [Revised: 01/15/2014] [Accepted: 01/20/2014] [Indexed: 11/22/2022]
|